1. Pink Sheet

Companies Face AUD100,000 Fine For Abusing Medicines Australia’s Complaint System

 
• By Neena Brizmohun

Australia’s industry group has updated its code of conduct with a number of new provisions, including one that clarifies its stance on members using its complaints system to disrupt another company's business.

Business And Code Of Conduct Concept Symbols
Medicines Australia's code of conduct covers ethical marketing and promotion of prescription medicines. (Shutterstock)

Companies that file complaints against each other for violations of Medicines Australia’s code of conduct may face fines of up to AUD100,000 ($66,182) if these complaints are used as a competitive tool.

Key Takeaways

Medicines Australia’s revised code of conduct – edition 20 – will come into effect on 30 March 2025.

The revised code includes a...

Intercompany complaints “should not be used as a mechanism to distract another company from its normal business activities,” said the industry body, which has updated its

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Pink Sheet

More from Compliance

Austria To Fine Companies For Violating New Drug Stockpiling Rule

 
• By Neena Brizmohun

A new ordinance for addressing drug shortages in Austria requires drug companies distributing any of the hundreds of products listed in an accompanying annex to maintain adequate stock in the country to meet patient demand for four months.

US FDA’s Expanded Surprise Foreign Inspections: Impact And Enforcement Hoops

 
• By Anju Ghangurde

As the US FDA expands unannounced foreign inspections building on pilots in India and China, experts expect higher scrutiny of overseas sites and perhaps even an industry shakeout in the longer term, though staffing and enforcement challenges could slow things down.

Pharma Industry Argues Tax, Other Incentives Better Than Tariffs

 
• By Jessica Merrill

Pharmaceutical industry organizations offered alternatives to tariffs that could maintain a secure domestic supply chain in public comments filed in response to a federal 232 investigation.